ALX Oncology. has filed a patent for a method of treating urothelial cancer by administering a fusion polypeptide with specific SIRPa D1 and Fc domain variants, along with enfortumab vedotin. The patent also includes related kits for the treatment. GlobalData’s report on ALX Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights ALX Oncology Holdings Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ALX Oncology, Personalized cancer vaccines was a key innovation area identified from patents. ALX Oncology's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of urothelial cancer using fusion polypeptide and enfortumab vedotin

Source: United States Patent and Trademark Office (USPTO). Credit: ALX Oncology Holdings Inc

A recently filed patent (Publication Number: US20240010701A1) outlines a method for treating urothelial cancer in individuals by administering a fusion polypeptide containing specific SIRPa D1 domain variants and Fc domain variants, along with enfortumab vedotin. The Fc domain variants include mutations in human IgG1, IgG2, and IgG4 Fc regions, as per the EU index of Kabat. The method is targeted towards individuals with locally advanced or metastatic urothelial cancer, including bladder, renal pelvis, ureter, or urethra cancer, who have previously received immune checkpoint inhibitors or platinum-containing chemotherapy.

Furthermore, the patent specifies that the individual should not have received prior treatment with monomethylauristatin-based antibody-drug conjugates or therapeutic agents blocking the CD47-SIRPa interaction. The administration of enfortumab vedotin and the fusion polypeptide is detailed in specific dosages and cycles, emphasizing intravenous administration. The fusion polypeptide, forming a homodimer, comprises distinct amino acid sequences, ensuring a targeted approach to treating urothelial cancer in human individuals. This patent presents a novel method that combines the use of fusion polypeptides and enfortumab vedotin to address urothelial cancer, offering potential advancements in cancer treatment strategies.

To know more about GlobalData’s detailed insights on ALX Oncology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies